Heparin versus Danaproid for Prevention of Venous Thromboembolism after Hip Surgery

Nakase, Janet Y.; Toribatake, Yasumitsu; Mouri, Youko; Seki, Hidetoshi; Kitaoka, Kenichi; Tomita, Kyoko

doi:10.1177/230949900901700102

Cited by 11 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hip fractures in particular are also associated with potentially severe complications like deep vein thrombosis, pressure ulcers, and pulmonary embolism, whereas vertebral fractures can affect pulmonary function (Schlaich et al , 1998; Margolis et al , 2003; Anand and Buch, 2007; Nakase et al , 2009). Our findings showed an increased overall mortality in breast cancer patients following hospitalisation with bone fracture that was interestingly independent of other comorbidities and tumour characteristics (Table 3).…”

Section: Discussionmentioning

confidence: 99%

Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study

Colzani¹,

Clements²,

Johansson³

et al. 2016

Br J Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study

Colzani¹,

Clements²,

Johansson³

et al. 2016

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…A major advantage of danaparoid is its low rate of cross-reactivity with antibodies associated with immune-mediated heparin-induced thrombocytopenia [14]. Further, it has been reported that danaparoid sodium is unlikely to cause gastrointestinal hemorrhage, and it appears to be more effective and safer than heparin in terms of bleeding complications [15].…”

Section: Introductionmentioning

confidence: 99%

Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients

et al. 2019

View full text Add to dashboard Cite

BackgroundPortal vein thrombosis (PVT) is a common complication of cirrhosis. However, in patients with PVT and cirrhosis, there is no clear evidence supporting effective treatment modalities. In this study, we examined the effectiveness and safety of anticoagulation therapy using danaparoid sodium for PVT in patients with cirrhosis.MethodsThis retrospective study assessed 52 cirrhotic patients with PVT treated with danaparoid sodium for 2 weeks between November 2008 and September 2018. The primary outcome measure was the post-treatment status of PVT assessed by reduction in thrombus volume and safety of the therapeutic intervention. PVT status was evaluated with contrast-enhanced computed tomography (CECT). All patients received 1250 units of danaparoid sodium twice daily by intravenous injection for 14 days. Patients on antithrombin III (AT-III) combination therapy were additionally administered 1500 units of AT-III on days 1–5 and days 8–12. Effectiveness was evaluated by CECT from between days 13 and 18. The secondary outcome measure was the prognosis of PVT.ResultsAll patients showed reduction in PVT volume without complications. Return of plasma AT-III level to > 70% during the treatment period contributes to ≥75% reduction of PVT volume. The prognosis in PVT patients depends on hepatic reserve capacity. When limited to Child-Pugh B and C liver cirrhosis patients, a ≥ 75% reduction of PVT volume improved the prognosis.ConclusionsDanaparoid sodium-based anticoagulation therapy was effective and safe for PVT in patients with cirrhosis. Return of plasma AT-III level to the normal range during the treatment period contributes to reduction of PVT volume. A reduction of ≥75% in PVT volume may improve the prognosis of Child-Pugh B and C decompensated cirrhosis patients with PVT.

show abstract

“…28 Danaparoid has been found to have less influence on platelets compared with other anticoagulants because it inhibits factor Xa selectively. 29 However, given the low incidence of HIT after TJA, LMWH is still able to be used as the chemoprophylaxis after TJA in patients without a history of HIT. 11,13,14 This study had several limitations.…”

Section: Discussionmentioning

confidence: 99%

Incidence, Outcomes and Risk Factors of Heparin-Induced Thrombocytopenia After Total Joint Arthroplasty: A National Inpatient Sample Database Study

Chen

Wang

Shi

et al. 2021

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Backgrounds: Heparin-induced thrombocytopenia (HIT) is a severe immune-mediated complication of heparin exposure, leading to negative consequences after total hip (THA) and knee arthroplasty (TKA). Materials and Methods: A retrospective study was conducted using the National Inpatient Sample (NIS) database from 2005 to 2014. The incidence and outcomes of HIT after THA or TKA were documented. Logistic regression analysis was performed to identify the postoperative HIT risk factors. Results: A total of 59 3045 patients who underwent THA and 1228 707 patients who underwent TKA were identified. The cumulative incidences were 0.02% and 0.01%, respectively. The HIT group presented significantly higher Charlson Comorbidity Index and Elixhauser Comorbidity Index scores, longer hospital stays (LOS), and higher medical costs. HIT led to a significantly higher mortality rate after THA (2.17% vs 0.16%, P = .0091). In THA, the HIT risk factors were racial minority, AIDS, pulmonary circulation disorders (PCD), psychoses, and hypertension. In TKA, the HIT risk factors were racial minority, PCD, and weight loss. Conclusion: The incidence of HIT after THA and TKA is relatively low; however, HIT significantly increases inpatient mortality, LOS, and medical cost.

show abstract

Heparin versus Danaproid for Prevention of Venous Thromboembolism after Hip Surgery

Abstract: Danaproid sodium appeared more effective and safer than heparin, with no bleeding complications occurred.

Cited by 11 publications

References 8 publications

Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study

Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study

Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients

Incidence, Outcomes and Risk Factors of Heparin-Induced Thrombocytopenia After Total Joint Arthroplasty: A National Inpatient Sample Database Study

Contact Info

Product

Resources

About